Artificial Intelligence (AI) is no longer a futuristic concept in life sciences — it’s here, reshaping how drugs are developed, reviewed, and marketed. But with innovation comes oversight, and that’s where the FDA draft guidance AI in pharma makes headlines in 2025. For the first time, the FDA is laying down structured expectations around how AI can and should be used across the pharmaceutical value chain.ヘ